PLCG2

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Thursday, June 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Thursday, June 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

Global Diabetic Macular Edema Drug Pipeline Market Research Report 2022: Comprehensive Insights About 65+ Companies and 65+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Diabetes, Inflammation, PKI, BTK, PKC, RVO, II, Population, Central retinal vein occlusion, Survival, Retina, UNITY, Patient, Mergers and acquisitions, Chronic lymphocytic leukemia, Macular edema, Visual acuity, Pharmacokinetics, VEGF, Retinal haemorrhage, SAD, Adult, Intravitreal injection, Cell, Volunteering, Bcl-xL, AMD, Protein kinase C, Diabetic retinopathy, NF-κB, Human, III, IVT, CLL, Technology, Safety, ABC, Kodiak, NDA, Biotechnology, Severe cognitive impairment, Therapy, Protein, Unity Biotechnology, Diabetes, Acquisition, PK, INTEGRAL, PLCG2, DME, Pharmaceutical industry, Vaccine, Meanings of minor planet names: 16001–17000

This ''Diabetic Macular Edema - Pipeline Insight, 2022" report provides comprehensive insights about 65+ companies and 65+ pipeline drugs in Diabetic Macular Edema pipeline landscape.

Key Points: 
  • This ''Diabetic Macular Edema - Pipeline Insight, 2022" report provides comprehensive insights about 65+ companies and 65+ pipeline drugs in Diabetic Macular Edema pipeline landscape.
  • A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines.
  • The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Diabetic Macular Edema.

MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Pharmaceutical, Optical, Finance, Health, Diabetes, Professional Services, Clinical Trials, PKC, PK, Safety, Protein kinase C, Lists of diseases, Degenerative disease, PLCG2, MD, CRT, Digital technology, Neuroscience, CEO, Diabetic retinopathy, MBA, Inflammation, CSO, Artificial intelligence, Program, Chronic lymphocytic leukemia, BTK, DME, Trust, VEGF, Ophthalmology, Visual acuity, Doctor of Philosophy, Lymphoid leukemia, Skin, Patient, CLL, Kidney, Retina, Pharmaceutical industry, MS-553, MingSight Pharmaceuticals, Kaitai Capital, MS-553, MINGSIGHT PHARMACEUTICALS, KAITAI CAPITAL

The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).

Key Points: 
  • The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).
  • We greatly appreciate the trust and support of our investors, said Kai Zhang, MD, MBA, CEO and Co-founder of MingSight.
  • We look forward to working with Kaitai and our other investors to accelerate the development of this unique compound.
  • MingSight is a clinical stage company focused on developing differentiated, novel therapies for serious diseases including B-cell malignancies, diabetic macular edema, and autoimmune diseases.